The transaction is sourced from an 8-K filing with the SEC, filed via SEC EDGAR and published on July 8, 2024. The deal's current status is pending regulatory approval.
On the financial advisory side, Centerview Partners LLC acted as exclusive financial advisor to Morphic, the target, in a lead capacity. Evercore Group L.L.C. also provided advice to Morphic, in a non-lead capacity, per a separate source sentence noting its additional advisory role. Citi acted as exclusive financial advisor to Lilly, the acquirer, in a lead capacity.
On the legal side, Fenwick & West LLP acted as legal counsel, identified in the facts block under the target designation (Morphic), while Kirkland & Ellis LLP acted as legal counsel to Lilly, the acquirer.
Beyond the cash consideration implied by the cash tender offer subtype, with a disclosed deal value of $3,200,000,000, no further detail on the specific per-share tender price or minimum tender condition is provided in the facts block.
Several items are not disclosed in the available record. No further structural detail beyond the cash tender offer classification and disclosed value is given, and no expected closing date or further timeline detail beyond the July 2024 filing date and pending-regulatory status is provided.